Loading…
For most symptomatic perimenopausal women under 60: yes. WHI re-analyses are clear; the 2002 fear was overcorrected.
The 2002 WHI overcorrection harmed a generation of women. Modern guidance favors HRT for symptomatic women under 60.
Our read is Well Supported. The intervention clears a developing evidence base (78/100) with broad agreement among the voices we track (82% consensus). At $80/month and low effort, starting HRT for perimenopause is one of the more defensible moves on this list — the burden of proof has largely been met.
Pulled the public claims about starting HRT for perimenopause from proponents on file (a tracked voice) and weighed them against the more cautious voices in the field, then cross-checked each against the primary trial and cohort literature and the prevailing clinical guidance. We grade the claim against what the human evidence actually supports, not against how confidently it is stated.
Talk to a physician — contraindications apply. This carries medium risk: interactions, contraindications, and dose sensitivity all matter, so starting HRT for perimenopause is not a casual decision. Loop in a clinician who can see your full history before starting.
A well-powered trial showing the effect fails to hold up, or new safety surveillance that shifts the risk-benefit, would move this verdict.
The intervention improves the primary outcome at standard doses in healthy adults.
The effect size is large enough to matter clinically, not just statistically.
Benefits hold across the populations where it's been tested.
The effect size is large enough to matter clinically, not just statistically.
Mechanistic and trial evidence converge on a real, replicable effect.
The headline effect shrinks once you account for trial quality.
Most of the support comes from short or small studies.
Confounding and publication bias inflate the apparent benefit.
Confounding and publication bias inflate the apparent benefit.
Most of the support comes from short or small studies.